[go: up one dir, main page]

AR064895A2 - Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina - Google Patents

Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina

Info

Publication number
AR064895A2
AR064895A2 ARP080100161A ARP080100161A AR064895A2 AR 064895 A2 AR064895 A2 AR 064895A2 AR P080100161 A ARP080100161 A AR P080100161A AR P080100161 A ARP080100161 A AR P080100161A AR 064895 A2 AR064895 A2 AR 064895A2
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
treatment
anhidra
induced disorders
histamine induced
Prior art date
Application number
ARP080100161A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27365195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064895(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR064895A2 publication Critical patent/AR064895A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una composicion farmacéutica anhidra para el tratamiento de desordenes inducidos por histamina, que comprende una cantidad terapéuticamente efectiva de descarboetoxiloratadina, o una sal farmacéuticamente aceptable de la misma y un portador farmacéuticamente aceptable. Reivindicacion 5: La composicion farmacéutica de la reivindicacion 4, caracterizada porque el analgésico es ácido acetilsalicílico, acetaminofén, ibuprofeno, ketofén, naproxeno o una sal farmacéuticamente aceptable de los mismos.
ARP080100161A 1997-02-07 2008-01-14 Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina AR064895A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3732597P 1997-02-07 1997-02-07
US4518497P 1997-04-30 1997-04-30
US5305097P 1997-07-21 1997-07-21

Publications (1)

Publication Number Publication Date
AR064895A2 true AR064895A2 (es) 2009-05-06

Family

ID=27365195

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980100521A AR011114A1 (es) 1997-02-07 1998-02-05 COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
ARP080100162A AR064896A2 (es) 1997-02-07 2008-01-14 Composicion farmaceutica no higroscopica
ARP080100161A AR064895A2 (es) 1997-02-07 2008-01-14 Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP980100521A AR011114A1 (es) 1997-02-07 1998-02-05 COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
ARP080100162A AR064896A2 (es) 1997-02-07 2008-01-14 Composicion farmaceutica no higroscopica

Country Status (28)

Country Link
US (2) US20020123504A1 (es)
EP (2) EP0969836B1 (es)
JP (1) JP2001511184A (es)
KR (5) KR20060076330A (es)
CN (1) CN1132579C (es)
AR (3) AR011114A1 (es)
AT (1) ATE345133T1 (es)
AU (1) AU6271998A (es)
BR (1) BR9806157A (es)
CA (1) CA2267136C (es)
CO (1) CO4940445A1 (es)
CZ (1) CZ119499A3 (es)
DE (1) DE69836424T2 (es)
DK (1) DK0969836T3 (es)
ES (1) ES2271986T3 (es)
HU (1) HUP0001527A3 (es)
MY (1) MY136999A (es)
NO (2) NO325611B1 (es)
NZ (1) NZ335041A (es)
PE (1) PE71699A1 (es)
PL (1) PL192075B1 (es)
PT (1) PT969836E (es)
RU (1) RU2209627C2 (es)
SK (1) SK286035B6 (es)
TW (1) TW522014B (es)
UA (1) UA70290C2 (es)
WO (1) WO1998034614A1 (es)
ZA (1) ZA98977B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507885A (en) * 1998-07-10 2001-08-31 Schering Corp 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (descarbonylethoxyloratadine) pharmaceutical compositions; useful for treating allergic reactions
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2001021162A2 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions using desloratadine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
SK287105B6 (sk) 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
SK287684B6 (sk) 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
KR101199654B1 (ko) * 1999-12-20 2012-11-08 머크 샤프 앤드 돔 코포레이션 안정한 서방출형의 경구 투여용 조성물
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7955620B2 (en) * 2003-12-23 2011-06-07 Sun Pharmaceutical Industries Limited Stable oral composition
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
NZ552998A (en) * 2004-07-16 2010-11-26 Cipla Ltd Anti-histaminic composition
US20100129310A1 (en) * 2004-08-09 2010-05-27 Pavak Rajnikanth Mehta Stabilized desloratadine composition
US20070004671A1 (en) * 2005-05-20 2007-01-04 Agarwal Sudeep K Stable desloratadine compositions
CA2547274A1 (en) * 2005-05-20 2006-11-20 Dr. Reddy's Laboratories Limited Stable desloratadine compositions
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20080118555A1 (en) * 2005-10-20 2008-05-22 Glenmark Pharmaceuticals Limited Stable pharmaceutical composition containing desloratadine
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
US20070244144A1 (en) * 2006-04-10 2007-10-18 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
WO2007140987A1 (en) * 2006-06-07 2007-12-13 Sandoz Ag Stable and bioavailable formulations and a novel form of desloratadine
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
EA024980B1 (ru) 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
ATE525064T1 (de) 2009-07-01 2011-10-15 Tiefenbacher Alfred E Gmbh & Co Kg Pharmazeutische zusammensetzung mit desloratadin
PT2568970T (pt) 2010-05-10 2019-02-11 Lesvi Laboratorios Sl Formulações farmacêuticas estáveis contendo um anti-histamínico
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
CN102813640B (zh) * 2012-09-06 2016-12-21 无锡万全医药技术有限公司 一种含地氯雷他定的软胶囊及其制备方法
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
EP3506895A4 (en) 2016-09-01 2020-04-15 JDS Therapeutics, LLC MAGNESIUM BIOTINATE COMPOSITIONS AND METHOD FOR USE
CN113230235B (zh) * 2021-04-15 2022-11-11 海南普利制药股份有限公司 含地氯雷他定的复方缓释胶囊及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
HU194864B (en) * 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH06504772A (ja) * 1990-12-18 1994-06-02 ザ　ウエルカム　ファウンデーション　リミテッド 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤
RU2068689C1 (ru) * 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Способ получения таблеток парацетамола
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
DE4442999A1 (de) * 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles

Also Published As

Publication number Publication date
NO992157L (no) 1999-05-04
NZ335041A (en) 2000-09-29
PT969836E (pt) 2007-01-31
NO20075846L (no) 1999-05-04
NO325611B1 (no) 2008-06-23
KR100624259B1 (ko) 2006-09-13
PL192075B1 (pl) 2006-08-31
ES2271986T3 (es) 2007-04-16
PE71699A1 (es) 1999-08-03
EP1614421A3 (en) 2006-02-15
AR011114A1 (es) 2000-08-02
AU6271998A (en) 1998-08-26
ZA98977B (en) 1998-07-30
PL334232A1 (en) 2000-02-14
KR20070086880A (ko) 2007-08-27
HUP0001527A2 (hu) 2001-04-28
US20020123504A1 (en) 2002-09-05
KR20060132053A (ko) 2006-12-20
CO4940445A1 (es) 2000-07-24
HUP0001527A3 (en) 2002-01-28
KR20060076330A (ko) 2006-07-04
BR9806157A (pt) 2001-01-09
KR20080003012A (ko) 2008-01-04
DK0969836T3 (da) 2007-03-19
NO992157D0 (no) 1999-05-04
SK286035B6 (sk) 2008-01-07
SK47299A3 (en) 2000-03-13
CN1132579C (zh) 2003-12-31
DE69836424T2 (de) 2007-09-27
EP0969836A1 (en) 2000-01-12
MY136999A (en) 2008-12-31
RU2209627C2 (ru) 2003-08-10
CZ119499A3 (cs) 1999-08-11
CA2267136C (en) 2000-11-28
EP1614421A2 (en) 2006-01-11
UA70290C2 (uk) 2004-10-15
ATE345133T1 (de) 2006-12-15
AR064896A2 (es) 2009-05-06
EP0969836B1 (en) 2006-11-15
TW522014B (en) 2003-03-01
HK1024187A1 (en) 2000-10-05
WO1998034614A1 (en) 1998-08-13
JP2001511184A (ja) 2001-08-07
KR20000068914A (ko) 2000-11-25
DE69836424D1 (de) 2006-12-28
CN1246794A (zh) 2000-03-08
US20060079489A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
AR033796A1 (es) Composicion farmaceutica
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
ES2194536T3 (es) Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
CU23226B7 (es) COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
CO5160329A1 (es) Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
LV10050A (lv) Farmaceitiska kompozicija ar zemam orala antikoagulanta un trombocitu inhibitora devam
NZ235877A (en) Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
MX9203278A (es) Pastilla de liberacion sustentada que comprende loratadina, ibuprofen y pseudoefedrina.
AR012376A1 (es) Formulacion de gel para la aplicacion topica
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
ES2033682T3 (es) Procedimiento para preparar una composicion farmaceutica que contiene acido 2-(2-fluoro-4-bifenilil)propionico o una de sus sales.
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
DK0710108T3 (da) Flydende, farmaceutisk præparat til oral anvendelse indeholdende 2-(4-isobutylphenyl)-propionsyre
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ITMI930582A0 (it) Composizione farmeceutiche ad attivita' analgesica
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
ITMI931325A0 (it) Composizione farmaceutica ad attivita' analgesica
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure